Obesity
Obesity and beyond
Embracing multi-indication potential during clinical development
The obesity therapeutic marketplace has rapidly embraced multi-indication drug development, following successful label expansion of incretin agonists semaglutide and tirzepatide. Explore the rise of multi-indication drug development across cardiometabolic-related conditions and the strategies driving clinical and commercial success for molecules with broad potential.
.jpeg?crop=yes&w=1017&h=1017&a=325,0&itok=lSLQEKvO "obesity_scan_icons"){kind=icon}
Survey report
How today¡¯s obesity developers are navigating a multi-indication landscape
From January 24 to March 5, 2025, ÃÛÌÒ´«Ã½ conducted a survey of 155 developers in obesity and related comorbidities. Survey respondents shared their clinical development and commercialisation strategies for molecules with broad clinical and commercial potential, and factors influencing whether or not to pursue multi-indication development of agents in their pipeline.
.jpeg?crop=yes&w=1251&h=1251&a=399,0&itok=bz2qsxFj "obesity scan person"){kind=icon}
A multifaceted risk factor:
Addressing obesity's impact across the disease spectrum
2.8 million people die every year as a result of obesity. At the same time, investment in research and development for obesity therapies is ushering in a new era of effective medications for this disease. Explore the implications of obesity as a risk factor across the disease spectrum, and how this may impact treatment, drug development and clinical trials for obesity.
ÃÛÌÒ´«Ã½ survey report:
Trends and challenges in obesity research and clinical trials
This survey investigates the opinions, experiences and predictions of a variety of individuals best positioned to provide an overview of current obesity drug and device development ¡ª and where it is likely to go in the future.
Obesity blogs and media contributions
-
Blog: Obesity-related liver conditions: Understanding treatment options
Explore obesity¡¯s role in liver disease progression and the value of different treatment options providing renewed hope to patients.
-
Blog: Designing clinical trials for a complex disease: Pediatric obesity
Pediatric obesity is a complex disease with multiple factors for sponsors to consider when designing and executing treatment trials.
-
Blog: A dynamic market: Trends transforming the future of obesity drug development
Learn about the future of obesity drug development and explore how GLP-1 drugs and multi-indication therapies are transforming treatment.
Interdisciplinary expertise in obesity research services
ÃÛÌÒ´«Ã½¡¯s highly experienced clinical and therapeutic teams have expertise in conducting trials across a wide range of therapeutic areas including obesity, diabetes, cardiometabolic disorders and hepatology including MASH.